Industries

eurotechnology.com

Pharmaceutical industry



Japan’s pharmaceutical market is the third largest globally:

  • USA US$ 425 billion (2020)
  • Europa US$ 200 billion (2020)
  • Japan US$ 150 billion (2020)
  • China US$ 120 billion (2924)

The 10 largest (by annual sales) Japanese pharmaceutical companies are

  1. Chugai (Hoffmann-La Roche holds 61.16% of shares excluding treasury stock, 59.89% of outstanding shares) sales US$ 5.2 billion (2022)
  2. Takeda US$ 5 billion
  3. Eisai US$ 4 billion
  4. Astellas US$ 3.8 billion
  5. Otsuka Holdings US$ 3.6 billion
  6. Daiichi Sankyo US$ 3.2 billion
  7. Mitsubishi Tanabe Pharma (absorbed by Mitsubishi Chemical) US$ 2.7 billion
  8. Sawai Pharmaceutical US$ 2 billion
  9. Kyowa Hakko Kirin US$ 1.8 billion
  10. Shionogi US$ 1.6 billion

We have assisted a European pharma multinational to acquire a Japanese pharma company/factory.

In the last years we are working with a European regenerative medicine venture, with a cell therapy platform, developing cell therapies for immune system diseases. We are working on building cooperation with Japanese pharma companies and we are working on the next funding round.

We are in preparations for a number of other business development projects for pharmaceutical companies, US, Japanese and European.

Japan’s pharmaceutical industry is on a journey bringing fundamental changes and opportunities, driven by a “therapy gap” and by global paradigm changes in pharmaceutical research and modalities, eg the invention of antibody therapies, and a revolution in genetic science, driven eg by Next Generation Sequencing (NGS), AI and bio-banks.

Not so long ago Japan’s pharma business model was to keep foreign pharma companies out and support the growth of domestic Japanese pharma companies, we are in the middle of a fundamental paradigm shift:

  • measures to overcome Japan’s “therapy gap” (ie there is a substantial number of advanced therapies approved in Europe and in USA, but not on the market in Japan).
  • accelerate the growth of global pharma companies based on R&D and discoveries in Japan
  • accelerating and international cooperation for the drug approval process

more: https://www.eurotechnology.com/japan-pharmaceutical-industry/

Medical devices / MedTech and Software as Medical Device (SaMD)


Japan’s medical device / MedTech market is the world’s second largest with an estimated market size around US$ 25 billion (2017) and growing between 1% – 2% per year. About 50% of medical devices are imported into Japan from foreign manufacturers including Johnson & Johnson, Medtronic, Siemens and GE.

Japan’s digital device and service market for healthcare is estimated to be around US$ 1.5 by 2025, approx. 75% for prevention, health management and rehabilitation and about 25% for diagnosis and treatment.

Major Japanese medical device manufacturers include:

  1. Olympus Medical Systems (revenues approx US$ 5 billion)
  2. Hitachi Healthcare (revenues approx US$ 5 billion)
  3. Teruo (revenues approx US$ 5 billion)
  4. Canon (revenues approx US$ 4 billion)
  5. Fujifilm (revenues approx US$ 4 billion)
  6. Nipro (revenues approx US$ 3 billion)
  7. Hoya, Pentax Medical (revenues approx US$ 3 billion)
  8. Sysmex (revenues approx US$ 2 billion)
  9. Nihon Koden (revenues approx US$ 1.5 billion)
  10. Teijin (revenues approx US$ 1.3 billion)

more: https://www.eurotechnology.com/japan-medical-devices/

Financial industry


We have advised more than 100 portfolio managers including some of the worlds largest investment funds and Boards of Directors of investment funds, on investment target companies, including due diligence and analysis, on the impact of industry inflection points, on investment strategies into Japan’s rapidly growing venture investment ecosystem.

For investment fund managers we performed due diligence and analysis on Japanese, European and US technology companies.

For the Japan subsidiary of one of the largest global banks we analyzed their mobile banking system and found major malfunctions and serious security issues. We supported our customer in resolving the security issues, and preformed a long term IT advisory contract.

more: https://www.eurotechnology.com/japan-financial-industry/

Technology industries


Our customer: European manufacturer of high-precision components for Japan’s mobile phone base station market, and other telecommunications applications. Our customer needed an accurate and detailed mapping of Japan’s mobile phone base station market, in order to sell components for mobile phone base stations and other telecom network applications in Japan.

We delivered a detailed quantitative and qualitative mapping of Japan’s mobile phone base station market, segmented by manufacturer, technology, type of base station, mobile operator, installation history, and future projections.

more: https://www.eurotechnology.com/japan-technology-industries/

Environmental industries


With a team of Japanese and European PhDs, MBAs we deliver an understanding of all required areas of Japan’s environmental technology sectors, and we develop strategy proposals for entering these sectors.
Markets included many areas, renewable energy, recycling, soil pollution, radiation protection, waste collection and disposal management, land fill management, electricity co-generation, lean production.

In addition, we profiled a list of Japanese electronics corporations regarding their environmental strategies and impact, and part of our customer’s competitive analysis.

We deliver the environmental and regulatory due diligence report on the Japanese pharmaceutical factory, we find approximately ten different potential problem areas, and estimate the associated risks and potential costs, enabling our customer, the French company’s CEO, to negotiate a fair acquisition price, based on a thorough environmental due diligence assessment.

We selected and partnered with Japan’s leading environmental technology engineering company, and supervised the project management, and assisted our customer’s CEO with negotiation meetings with the the seller of the factory.

The acquisition was successfully completed and the factory is now under new ownership by our customer.

Software as a Service SaaS


Turn-round: “third restart” in Japan for a Silicon Valley based SaaS business process company (market cap US$ 15 billion).

This Bay Area B2B SaaS company (NASDAQ listed, market cap around US$ 15 billion) asked us for help for the “third restart” in Japan. The company had started in Japan about 10 years earlier, was not growing as fast as hoped and asked us to create a new “go-to-market plan”, and strategy for their “third restart” in Japan.

We determined the company’s competitive positions, market shares, true market positioning, recommended focus on priority verticals, talked with Japanese customers to understand Japanese customer’s pain points with the company’s products, found several problems of the company’s products which needed fixing, recommended an acquisition to address missing functionality needed by Japanese customers. We created a go-to-market plan focussed on priority verticals, and addressed issues with the management structure for Japan, holding back growth in Japan.

more: https://www.eurotechnology.com/saas/